Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Editorial: Targeting Myeloid Cells to Fight Cancer.

Hollmén M, Zheng W, Pollard JW.

Front Immunol. 2019 Dec 3;10:2835. doi: 10.3389/fimmu.2019.02835. eCollection 2019. No abstract available.

2.

A Metastable Atrial State Underlies The Primary Genetic Substrate for MYL4 Mutation-Associated Atrial Fibrillation.

Ghazizadeh Z, Kiviniemi TO, Olafsson S, Plotnick D, Beerens M, Zhang K, Gillon L, Steinbaugh M, Barrera V, Ho Sui S, Werdich AA, Kapur S, Eranti A, Gunn J, Jalkanen J, Airaksinen J, Kleber AG, Hollmén M, MacRae CA.

Circulation. 2019 Nov 16. doi: 10.1161/CIRCULATIONAHA.119.044268. [Epub ahead of print]

PMID:
31735076
3.

Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils.

Takeda A, Hollmén M, Dermadi D, Pan J, Brulois KF, Kaukonen R, Lönnberg T, Boström P, Koskivuo I, Irjala H, Miyasaka M, Salmi M, Butcher EC, Jalkanen S.

Immunity. 2019 Sep 17;51(3):561-572.e5. doi: 10.1016/j.immuni.2019.06.027. Epub 2019 Aug 8.

PMID:
31402260
4.

Clever-1 contributes to lymphocyte entry into the spleen via the red pulp.

Tadayon S, Dunkel J, Takeda A, Halle O, Karikoski M, Gerke H, Rantakari P, Virtakoivu R, Pabst O, Salmi M, Hollmén M, Jalkanen S.

Sci Immunol. 2019 Mar 29;4(33). pii: eaat0297. doi: 10.1126/sciimmunol.aat0297.

PMID:
30926591
5.

Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors.

Viitala M, Virtakoivu R, Tadayon S, Rannikko J, Jalkanen S, Hollmén M.

Clin Cancer Res. 2019 Jun 1;25(11):3289-3303. doi: 10.1158/1078-0432.CCR-18-3016. Epub 2019 Feb 12.

PMID:
30755440
6.

Serum cytokine levels differ according to major cardiovascular risk factors in patients with lower limb atherosclerosis.

Jalkanen J, Hollmén M, Maksimow M, Jalkanen S, Hakovirta H.

Cytokine. 2019 Feb;114:74-80. doi: 10.1016/j.cyto.2018.11.001. Epub 2018 Nov 13.

PMID:
30442459
7.

Enhanced Antibody Production in Clever-1/Stabilin-1-Deficient Mice.

Dunkel J, Viitala M, Karikoski M, Rantakari P, Virtakoivu R, Elima K, Hollmén M, Jalkanen S, Salmi M.

Front Immunol. 2018 Oct 8;9:2257. doi: 10.3389/fimmu.2018.02257. eCollection 2018.

8.

Six-Week Endurance Exercise Alters Gut Metagenome That Is not Reflected in Systemic Metabolism in Over-weight Women.

Munukka E, Ahtiainen JP, Puigbó P, Jalkanen S, Pahkala K, Keskitalo A, Kujala UM, Pietilä S, Hollmén M, Elo L, Huovinen P, D'Auria G, Pekkala S.

Front Microbiol. 2018 Oct 3;9:2323. doi: 10.3389/fmicb.2018.02323. eCollection 2018.

9.

Enterobacter cloacae administration induces hepatic damage and subcutaneous fat accumulation in high-fat diet fed mice.

Keskitalo A, Munukka E, Toivonen R, Hollmén M, Kainulainen H, Huovinen P, Jalkanen S, Pekkala S.

PLoS One. 2018 May 30;13(5):e0198262. doi: 10.1371/journal.pone.0198262. eCollection 2018.

10.

Melanocortin 1 Receptor Deficiency Promotes Atherosclerosis in Apolipoprotein E-/- Mice.

Rinne P, Kadiri JJ, Velasco-Delgado M, Nuutinen S, Viitala M, Hollmén M, Rami M, Savontaus E, Steffens S.

Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):313-323. doi: 10.1161/ATVBAHA.117.310418. Epub 2017 Dec 28.

11.

New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate.

Cui J, Hollmén M, Li L, Chen Y, Proulx ST, Reker D, Schneider G, Detmar M.

Oncotarget. 2017 Jan 3;8(1):1007-1022. doi: 10.18632/oncotarget.13537.

12.

Regulation of CD73 in the development of lower limb atherosclerosis.

Jalkanen J, Hollmén M, Jalkanen S, Hakovirta H.

Purinergic Signal. 2017 Mar;13(1):127-134. doi: 10.1007/s11302-016-9545-0. Epub 2016 Nov 10.

13.

Disposal of iron by a mutant form of lipocalin 2.

Barasch J, Hollmen M, Deng R, Hod EA, Rupert PB, Abergel RJ, Allred BE, Xu K, Darrah SF, Tekabe Y, Perlstein A, Wax R, Bruck E, Stauber J, Corbin KA, Buchen C, Slavkovich V, Graziano J, Spitalnik SL, Bao G, Strong RK, Qiu A.

Nat Commun. 2016 Oct 31;7:12973. doi: 10.1038/ncomms12973.

14.

Lymphatic endothelial cells attenuate inflammation via suppression of dendritic cell maturation.

Christiansen AJ, Dieterich LC, Ohs I, Bachmann SB, Bianchi R, Proulx ST, Hollmén M, Aebischer D, Detmar M.

Oncotarget. 2016 Jun 28;7(26):39421-39435. doi: 10.18632/oncotarget.9820.

15.

Soluble CD73 in Critically Ill Septic Patients - Data from the Prospective FINNAKI Study.

Vaara ST, Hollmén M, Korhonen AM, Maksimow M, Ala-Kokko T, Salmi M, Jalkanen S, Pettilä V; FINNAKI Study Group.

PLoS One. 2016 Oct 12;11(10):e0164420. doi: 10.1371/journal.pone.0164420. eCollection 2016.

16.

Compared to Intermittant Claudication Critical Limb Ischemia Is Associated with Elevated Levels of Cytokines.

Jalkanen J, Maksimow M, Hollmén M, Jalkanen S, Hakovirta H.

PLoS One. 2016 Sep 9;11(9):e0162353. doi: 10.1371/journal.pone.0162353. eCollection 2016.

17.

Transgenic overexpression of VEGF-C induces weight gain and insulin resistance in mice.

Karaman S, Hollmén M, Yoon SY, Alkan HF, Alitalo K, Wolfrum C, Detmar M.

Sci Rep. 2016 Aug 11;6:31566. doi: 10.1038/srep31566.

18.

G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer.

Hollmén M, Karaman S, Schwager S, Lisibach A, Christiansen AJ, Maksimow M, Varga Z, Jalkanen S, Detmar M.

Oncoimmunology. 2015 Nov 24;5(3):e1115177. eCollection 2016 Mar.

19.

Transcriptional profiling of macrophage and tumor cell interactions in vitro.

Roudnicky F, Hollmén M.

Genom Data. 2016 Feb 22;8:1-3. doi: 10.1016/j.gdata.2016.02.009. eCollection 2016 Jun.

20.

Drug Pharmacokinetics Determined by Real-Time Analysis of Mouse Breath.

Li X, Martinez-Lozano Sinues P, Dallmann R, Bregy L, Hollmén M, Proulx S, Brown SA, Detmar M, Kohler M, Zenobi R.

Angew Chem Int Ed Engl. 2015 Jun 26;54(27):7815-8. doi: 10.1002/anie.201503312. Epub 2015 May 27.

PMID:
26015026
21.

Characterization of macrophage--cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer.

Hollmén M, Roudnicky F, Karaman S, Detmar M.

Sci Rep. 2015 Mar 17;5:9188. doi: 10.1038/srep09188.

22.

Blockade of VEGF-C and VEGF-D modulates adipose tissue inflammation and improves metabolic parameters under high-fat diet.

Karaman S, Hollmén M, Robciuc MR, Alitalo A, Nurmi H, Morf B, Buschle D, Alkan HF, Ochsenbein AM, Alitalo K, Wolfrum C, Detmar M.

Mol Metab. 2014 Dec 4;4(2):93-105. doi: 10.1016/j.molmet.2014.11.006. eCollection 2015 Feb.

23.

Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis.

Jalkanen J, Yegutkin GG, Hollmén M, Aalto K, Kiviniemi T, Salomaa V, Jalkanen S, Hakovirta H.

Circ Res. 2015 Mar 27;116(7):1206-15. doi: 10.1161/CIRCRESAHA.116.305715. Epub 2015 Feb 2.

PMID:
25645301
24.

Ecto-5'-nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature.

Yegutkin GG, Auvinen K, Rantakari P, Hollmén M, Karikoski M, Grénman R, Elima K, Jalkanen S, Salmi M.

Eur J Immunol. 2015 Feb;45(2):562-73. doi: 10.1002/eji.201444856. Epub 2014 Dec 15.

25.

Clever-1/stabilin-1 controls cancer growth and metastasis.

Karikoski M, Marttila-Ichihara F, Elima K, Rantakari P, Hollmén M, Kelkka T, Gerke H, Huovinen V, Irjala H, Holmdahl R, Salmi M, Jalkanen S.

Clin Cancer Res. 2014 Dec 15;20(24):6452-64. doi: 10.1158/1078-0432.CCR-14-1236. Epub 2014 Oct 15.

26.

Serum neutrophil gelatinase-associated lipocalin and recovery of kidney graft function after transplantation.

Hollmen ME, Kyllönen LE, Merenmies J, Salmela KT.

BMC Nephrol. 2014 Jul 28;15:123. doi: 10.1186/1471-2369-15-123.

27.

Neutrophil gelatinase-associated lipocalin associated with irreversibility of pre-liver transplant kidney dysfunction.

Aberg F, Lempinen M, Hollmén M, Nordin A, Mäkisalo H, Isoniemi H.

Clin Transplant. 2014 Aug;28(8):869-76. doi: 10.1111/ctr.12394. Epub 2014 Jul 3.

PMID:
24930480
28.

Fingerprinting breast cancer vs. normal mammary cells by mass spectrometric analysis of volatiles.

He J, Sinues PM, Hollmén M, Li X, Detmar M, Zenobi R.

Sci Rep. 2014 Jun 6;4:5196. doi: 10.1038/srep05196.

29.

The orphan adhesion G protein-coupled receptor GPR97 regulates migration of lymphatic endothelial cells via the small GTPases RhoA and Cdc42.

Valtcheva N, Primorac A, Jurisic G, Hollmén M, Detmar M.

J Biol Chem. 2013 Dec 13;288(50):35736-48. doi: 10.1074/jbc.M113.512954. Epub 2013 Oct 31.

30.

Proteolytic processing of ErbB4 in breast cancer.

Hollmén M, Liu P, Kurppa K, Wildiers H, Reinvall I, Vandorpe T, Smeets A, Deraedt K, Vahlberg T, Joensuu H, Leahy DJ, Schöffski P, Elenius K.

PLoS One. 2012;7(6):e39413. doi: 10.1371/journal.pone.0039413. Epub 2012 Jun 22.

31.

NGAL-Siderocalin in kidney disease.

Paragas N, Qiu A, Hollmen M, Nickolas TL, Devarajan P, Barasch J.

Biochim Biophys Acta. 2012 Sep;1823(9):1451-8. doi: 10.1016/j.bbamcr.2012.06.014. Epub 2012 Jun 19. Review.

32.

Effect of simvastatin on development of obliterative airway disease: an experimental study.

Ropponen JO, Syrjälä SO, Hollmén M, Tuuminen R, Krebs R, Keränen MA, Vaali K, Nykänen AI, Lemström KB, Tikkanen JM.

J Heart Lung Transplant. 2012 Feb;31(2):194-203. doi: 10.1016/j.healun.2011.11.008.

PMID:
22305382
33.

Diagnostic test for early detection of acute kidney injury.

Hollmen M.

Expert Rev Mol Diagn. 2011 Jul;11(6):553-5. doi: 10.1586/erm.11.35. No abstract available.

PMID:
21745008
34.

Deceased donor neutrophil gelatinase-associated lipocalin and delayed graft function after kidney transplantation: a prospective study.

Hollmen ME, Kyllönen LE, Inkinen KA, Lalla ML, Merenmies J, Salmela KT.

Crit Care. 2011;15(3):R121. doi: 10.1186/cc10220. Epub 2011 May 5.

35.

Urine neutrophil gelatinase-associated lipocalin is a marker of graft recovery after kidney transplantation.

Hollmen ME, Kyllönen LE, Inkinen KA, Lalla ML, Salmela KT.

Kidney Int. 2011 Jan;79(1):89-98. doi: 10.1038/ki.2010.351. Epub 2010 Sep 22.

36.

Potential of ErbB4 antibodies for cancer therapy.

Hollmén M, Elenius K.

Future Oncol. 2010 Jan;6(1):37-53. doi: 10.2217/fon.09.144. Review.

PMID:
20021208
37.

Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor.

Peltola K, Hollmen M, Maula SM, Rainio E, Ristamäki R, Luukkaa M, Sandholm J, Sundvall M, Elenius K, Koskinen PJ, Grenman R, Jalkanen S.

Neoplasia. 2009 Jul;11(7):629-36.

38.

Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms.

Hollmén M, Määttä JA, Bald L, Sliwkowski MX, Elenius K.

Oncogene. 2009 Mar 12;28(10):1309-19. doi: 10.1038/onc.2008.481. Epub 2009 Jan 19.

PMID:
19151766
39.

Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.

Tvorogov D, Sundvall M, Kurppa K, Hollmén M, Repo S, Johnson MS, Elenius K.

J Biol Chem. 2009 Feb 27;284(9):5582-91. doi: 10.1074/jbc.M805438200. Epub 2008 Dec 19.

40.

Tacrolimus treatment effectively inhibits progression of obliterative airway disease even at later stages of disease development.

Hollmén M, Tikkanen JM, Nykänen AI, Koskinen PK, Lemström KB.

J Heart Lung Transplant. 2008 Aug;27(8):856-64. doi: 10.1016/j.healun.2008.05.018. Epub 2008 Jul 3.

PMID:
18656798
41.

VEGFR-1 and -2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts.

Raisky O, Nykänen AI, Krebs R, Hollmén M, Keränen MA, Tikkanen JM, Sihvola R, Alhonen L, Salven P, Wu Y, Hicklin DJ, Alitalo K, Koskinen PK, Lemström KB.

Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):819-25. Epub 2007 Feb 8.

PMID:
17290032
42.

Vascular endothelial growth factor plays a major role in development of experimental obliterative bronchiolitis.

Krebs R, Hollmén ME, Tikkanen JM, Wu Y, Hicklin DJ, Koskinen PK, Lemström KB.

Transplant Proc. 2006 Dec;38(10):3266-7.

PMID:
17175244
43.

Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease.

Tikkanen JM, Hollmén M, Nykänen AI, Wood J, Koskinen PK, Lemström KB.

Am J Respir Crit Care Med. 2006 Nov 15;174(10):1145-52. Epub 2006 Aug 17.

PMID:
16917119
44.

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J.

Ann Oncol. 2005 Feb;16(2):273-8.

PMID:
15668283
45.

Suppression of viability and acetyl-LDL metabolism in RAW 264 macrophage-like and smooth muscle cells by bisphosphonates in vitro.

Tuominen OM, Hollmén M, Jaakkola O, Mönkkönen J, Ylitalo R.

Methods Find Exp Clin Pharmacol. 2002 Oct;24(8):487-92.

PMID:
12500427

Supplemental Content

Loading ...
Support Center